A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy
An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy
This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.
調査の概要
詳細な説明
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen (PSMA) and folate receptor alpha (FR-alpha) and carrying monomethyl auristatin E (MMAE). MVB-101 will be administered by direct injection into the prostate under transrectal ultrasound guidance, at a fixed total injection volume of 10 mL (5 mL per lobe), once per week for 4 weeks.
Part A will enroll up to 30 participants. Planned dose levels are 1, 2, 4, and 8 mg per dose. The dose-limiting toxicity evaluation period is Day 1 through Day 29. Accelerated titration rules will be applied to the first two dose levels, and an i3+3 design will guide dose selection. Higher, lower, or intermediate dose levels may be added based on emerging data and Safety Monitoring Committee recommendations. The recommended Phase 2 dose may be the same as or lower than the maximum tolerated dose.
Part B will enroll up to 29 participants per dose group at one or more selected dose levels and will use a Simon two-stage design to better estimate the recommended Phase 2 dose and further characterize safety and preliminary efficacy.
The study includes screening, treatment, safety follow-up approximately 28 days after the last dose, post-treatment multiparametric MRI and PSA assessment, and planned radical prostatectomy at approximately Day 90 (12 weeks). If radical prostatectomy is not performed, a post-treatment prostate biopsy will be obtained as close as possible to the planned prostatectomy date. End of study occurs after completion of safety follow-up, post-treatment MRI and PSA assessment, and prostatectomy or post-treatment biopsy.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Aimee Murphy
- 電話番号:925-818-4403
- メール:amurphy@mvbiotx.com
研究場所
-
-
Alabama
-
Homewood、Alabama、アメリカ、35209
- 募集
- Urology Centers of Alabama
-
コンタクト:
- Meredith Sharpton, PA-C
- 電話番号:205-445-0129
- メール:msharpton@urologyal.com
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- Urology San Antonio
-
コンタクト:
- Manuel Hernandez
- 電話番号:210-617-4116
- メール:Manuel.hernandez@usa-clinicaltrials.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed informed consent form.
- Understands the obligation and is capable of attending all follow-up visits.
- Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
- Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
- Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density >0.2 ng/mL/cc, PI-RADS 4 or 5, lesion >1.0 cm, lesion volume >0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
- Prostate-specific antigen 20 ng/mL or less.
- Eastern Cooperative Oncology Group performance status 0 or 1.
- Adequate bone marrow and organ function.
- Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.
Exclusion Criteria:
- Any prior treatment for prostate cancer, except prior active surveillance is permitted.
- More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
- Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
- Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
- Prostatic calcifications.
- Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
- Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
- Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
- Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
- Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
- History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
- Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
- Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
- Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
- Active infection requiring intravenous antibiotics within 1 week before first dose.
- Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
- Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A: MVB-101 1 mg
MVB-101 1 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part A: MVB-101 2 mg
MVB-101 2 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part A: MVB-101 4 mg
MVB-101 4 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part A: MVB-101 8 mg
MVB-101 8 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part B: MVB-101 Dose Expansion
MVB-101 at one or more selected dose levels by intraprostatic injection once weekly for 4 weeks. Other schedules may also be explored. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment-emergent adverse events
時間枠:From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
|
Number and percentage of participants with treatment-emergent adverse events, treatment-related adverse events, serious adverse events, and clinically significant changes in vital signs, physical examinations, electrocardiogram (ECG) and clinical laboratory tests, graded using NCI CTCAE version 6.0. |
From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
|
|
Dose-limiting toxicities
時間枠:Day 1 through Day 29
|
Number and percentage of participants with a dose-limiting toxicity, assessed according to protocol-defined criteria using NCI CTCAE version 6.0. |
Day 1 through Day 29
|
|
Maximum tolerated dose
時間枠:Through completion of Part A dose escalation, up to 12 months
|
Maximum tolerated dose of intraprostatic MVB-101 determined from dose-limiting toxicities and cumulative safety data under the i3+3 design. |
Through completion of Part A dose escalation, up to 12 months
|
|
Recommended Phase 2 dose
時間枠:Through completion of dose escalation and applicable dose-expansion, up to 18 months
|
Recommended Phase 2 dose of intraprostatic MVB-101 based on safety, tolerability, pharmacokinetics, and available efficacy data. |
Through completion of dose escalation and applicable dose-expansion, up to 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetic parameters of MVB-101 and MMAE
時間枠:Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
|
Plasma concentration-time analysis will be performed using PK concentration values over time. |
Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
|
|
Pathological response in excised prostate tissue
時間枠:At prostatectomy or post-treatment biopsy, approximately Day 90
|
Number and percentage of participants with persistence or absence of the dominant index prostate cancer lesion or any lesion on pathological examination of prostatectomy tissue; post-treatment multicore biopsy is used if planned prostatectomy is not performed. |
At prostatectomy or post-treatment biopsy, approximately Day 90
|
|
Radiologic response by multiparametric MRI
時間枠:Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
|
Number and percentage of participants with persistence or absence of baseline prostate cancer lesions on post-treatment multiparametric MRI. |
Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
|
|
International Prostate Symptom Score
時間枠:Baseline through safety follow-up (approximately Day 50)
|
Observed values and change from baseline in International Prostate Symptom Score (IPSS). IPSS score values between 0-5 with lower scores indicating better performance/ improvement. |
Baseline through safety follow-up (approximately Day 50)
|
|
International Index of Erectile Function-5
時間枠:Baseline through safety follow-up (approximately Day 50)
|
Observed values and change from baseline in International Index of Erectile Function-5 (IIEF-5). IIEF-5 is scored with values 1-5 with higher scores indicating better performance/ improvement. |
Baseline through safety follow-up (approximately Day 50)
|
協力者と研究者
捜査官
- スタディディレクター:Stephen Snowdy, PhD、MultiValent Biotherapies, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- MVB-101-101
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。